share_log

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression

Cybin Inc.がフェーズ3の試験を開始し、CYB003によるうつ病治療に大きな賭けをしています

Benzinga ·  11/13 07:31

Cybin Inc.(AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development.

"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone," saidDoug Drysdale, CEO of Cybin.

The design of the PARADIGM program, according to Drysdale, has been shaped by a collaborative process with theFood and Drug Administration (FDA), taking into account the challenges faced by other...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする